A 67-year-old considering when to claim Social Security faces a choice: start now or wait until 70 to increase monthly benefits by about 24%. Although 10-year Treasury yields have risen near 5%, the guaranteed lifetime increase from delaying Social Security outweighs potential earnings from bonds. Waiting three years raises monthly checks significantly and benefits both the claimant and their spouse, especially in terms of survivor benefits. The decision depends on personal factors like savings, health, taxes, and marital status, with careful planning advised.
The story about a 67-year-old weighing Social Security timing comes with a market snapshot from Pluang. As of Nov 13, 2026 16:51 WIB, 100 of 150 priced US stocks on Pluang rose while 45 fell. Notable price moves include AMD at USD 570.99 down 2.44%, Nvidia at USD 170.13 up 2.37%, and Li Auto at USD 11.42 down 2.31%.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
